{"log_id": 1376833871056397646, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0.012845, "average": 0.890762, "min": 0.674443}, "location": {"width": 448, "top": 162, "height": 41, "left": 107}, "words": "图1: Kaplan- Meier无进展生存曲线"}, {"probability": {"variance": 0, "average": 0.436938, "min": 0.436938}, "location": {"width": 25, "top": 281, "height": 22, "left": 893}, "words": " IT"}, {"probability": {"variance": 0.028137, "average": 0.833585, "min": 0.478773}, "location": {"width": 137, "top": 304, "height": 27, "left": 788}, "words": "55%C1.25"}, {"probability": {"variance": 9e-06, "average": 0.997733, "min": 0.99235}, "location": {"width": 224, "top": 964, "height": 36, "left": 148}, "words": "中国临床研究结果"}, {"probability": {"variance": 0.005873, "average": 0.964065, "min": 0.576966}, "location": {"width": 1243, "top": 1017, "height": 57, "left": 146}, "words": "本品在中国进行的一项多中心、开放性、无对约临床试验中,入选64名应用管内皮生长因子受"}, {"probability": {"variance": 0.031175, "average": 0.898414, "min": 0.37758}, "location": {"width": 1296, "top": 1072, "height": 57, "left": 91}, "words": "体酪氨酸激酶抑制剂( VEGFR-TKI)治疗(舒尼替尼、点拉非尼或两者都使用过)后逊展的转移性肾胞"}, {"probability": {"variance": 0.019894, "average": 0.920794, "min": 0.419774}, "location": {"width": 1296, "top": 1126, "height": 59, "left": 91}, "words": "患者,受试者中位龄51.5岁(范围为19岁至75岁)。在本次研究中每日一次应月本品10mg。允许之前"}, {"probability": {"variance": 0.014955, "average": 0.933801, "min": 0.423391}, "location": {"width": 1293, "top": 1181, "height": 57, "left": 91}, "words": "使用过贝伐单抗和α干扰素的患者入选。总体缓解率和疾控制率分别为47和65.6%中位无进生存"}, {"probability": {"variance": 0.017373, "average": 0.952088, "min": 0.389312}, "location": {"width": 541, "top": 1238, "height": 43, "left": 91}, "words": "期为6.93个月,12个月的总率为556%"}, {"probability": {"variance": 0.016687, "average": 0.9197, "min": 0.506885}, "location": {"width": 454, "top": 1293, "height": 41, "left": 86}, "words": "局部晚斯或转移性胰腺神经内分泌瘤"}, {"probability": {"variance": 0, "average": 0.735402, "min": 0.735402}, "location": {"width": 100, "top": 1296, "height": 43, "left": 1051}, "words": "空"}, {"probability": {"variance": 0.01959, "average": 0.921706, "min": 0.411975}, "location": {"width": 1216, "top": 1346, "height": 54, "left": 139}, "words": "在局部晚或发生转移的进展期胰腺神经内分泌瘤且之前12个月内疾病进的思中进行了一项随机"}, {"probability": {"variance": 0.026633, "average": 0.901294, "min": 0.396136}, "location": {"width": 1296, "top": 1401, "height": 54, "left": 86}, "words": "双、多中心试,比较本品加持疗法(BSC)与安慰剂加最佳支持法。按照既往细胞毒性化疗(是"}, {"probability": {"variance": 0.017536, "average": 0.90997, "min": 0.476089}, "location": {"width": 1298, "top": 1458, "height": 54, "left": 82}, "words": "香)及WH体力状态(对比1和2)对患者进行分层。允许生长素类似物作为最佳支持疗法的一部分。试"}, {"probability": {"variance": 0.013978, "average": 0.93706, "min": 0.412868}, "location": {"width": 1293, "top": 1513, "height": 54, "left": 84}, "words": "验的主要终点是按体瘤疗效评价标准 (RECIST1.0版)评价的无进展生存PFS)。在放射学检查记录到"}, {"probability": {"variance": 0.021117, "average": 0.924616, "min": 0.416731}, "location": {"width": 1268, "top": 1568, "height": 52, "left": 82}, "words": "病进展后,研究者可揭盲受试者;那些随机至安慰剂组的患考防后可开放性使用本品。其它终点包括安全"}, {"probability": {"variance": 0.032309, "average": 0.877962, "min": 0.359386}, "location": {"width": 1037, "top": 1622, "height": 50, "left": 82}, "words": "客观有效率(ORR(先全缓(C)或部分缓解(P))、疗效持续时间和总体生存"}, {"probability": {"variance": 0.018215, "average": 0.9198, "min": 0.524288}, "location": {"width": 1234, "top": 1680, "height": 52, "left": 137}, "words": "患者按照1:1随机服用依维莫可10mg/日(n=207)或安慰剂(=203)人门统计学持征平衡良好(中"}, {"probability": {"variance": 0.001006, "average": 0.976557, "min": 0.902806}, "location": {"width": 523, "top": 1732, "height": 43, "left": 82}, "words": "位年龄58岁,55%为男性:79%为高加人"}, {"probability": {"variance": 0.022403, "average": 0.890228, "min": 0.545686}, "location": {"width": 697, "top": 1741, "height": 43, "left": 660}, "words": "73(148/2035)患轨安慰剂组交叉全开放服用本品治疗"}, {"probability": {"variance": 0.025941, "average": 0.914044, "min": 0.400678}, "location": {"width": 1222, "top": 1787, "height": 54, "left": 134}, "words": "该试验证明PS改善具有显著性统计学意义(中位11.0个月对比4.6个月),在研究者判定的PFS方面"}, {"probability": {"variance": 0.021402, "average": 0.913944, "min": 0.378698}, "location": {"width": 1296, "top": 1842, "height": 54, "left": 77}, "words": "风险可降低65%(HR.35:95%C:0.27-045:p<0.001)《参见表9和图2):所有者亚均规察到PFS改"}, {"probability": {"variance": 0.01836, "average": 0.925514, "min": 0.488961}, "location": {"width": 1296, "top": 1897, "height": 54, "left": 75}, "words": "萍,无论之前是否使用生长抑素类似物,研究者放射学评估PES结果、中心放射学评钻PS结果以及定的放"}, {"probability": {"variance": 0.010232, "average": 0.943926, "min": 0.636051}, "location": {"width": 313, "top": 1954, "height": 34, "left": 73}, "words": "射学评估PFS结果参见表"}, {"probability": {"variance": 0.017847, "average": 0.913607, "min": 0.535351}, "location": {"width": 276, "top": 2009, "height": 36, "left": 75}, "words": "表9:元进展生存结果"}, {"probability": {"variance": 0.006472, "average": 0.937068, "min": 0.791069}, "location": {"width": 141, "top": 2071, "height": 36, "left": 468}, "words": "依维莫司片"}, {"probability": {"variance": 1e-06, "average": 0.997554, "min": 0.99612}, "location": {"width": 86, "top": 2075, "height": 34, "left": 742}, "words": "安慰剂"}, {"probability": {"variance": 0.000483, "average": 0.98064, "min": 0.949794}, "location": {"width": 91, "top": 2077, "height": 34, "left": 985}, "words": "风险比"}, {"probability": {"variance": 0.029144, "average": 0.823011, "min": 0.652297}, "location": {"width": 57, "top": 2082, "height": 36, "left": 1232}, "words": "p值"}, {"probability": {"variance": 5e-06, "average": 0.996293, "min": 0.993346}, "location": {"width": 80, "top": 2114, "height": 27, "left": 498}, "words": "N=207"}, {"probability": {"variance": 2e-05, "average": 0.994463, "min": 0.986217}, "location": {"width": 73, "top": 2116, "height": 27, "left": 745}, "words": "N=203"}, {"probability": {"variance": 0.029437, "average": 0.901984, "min": 0.519779}, "location": {"width": 114, "top": 2121, "height": 29, "left": 976}, "words": "95%CT)"}], "language": 3}